share_log

Earnings Call Summary | NeuroOne Medical(NMTC.US) Q4 2024 Earnings Conference

Earnings Call Summary | NeuroOne Medical(NMTC.US) Q4 2024 Earnings Conference

業績會總結 | NeuroOne 醫療(NMTC.US) 2024年第四季度業績會
富途資訊 ·  2024/12/17 14:53  · 電話會議

The following is a summary of the NeuroOne Medical Technologies Corporation (NMTC) Q4 2024 Earnings Call Transcript:

以下是NeuroOne醫療技術公司(NMTC)2024年第四季度業績會文字記錄的摘要:

Financial Performance:

財務表現:

  • NeuroOne reported Q4 product revenue of $1.3 million, a reduction compared to the prior year, attributed to cancellation of order to transition to the new OneRF product line.

  • Fiscal year 2024 product revenue surged by 77% to $3.5 million.

  • Forecasted revenue for fiscal year 2025 is projected between $8 million to $10 million, representing a growth of 132% to 190%.

  • Gross margins are expected to improve in fiscal year 2025, ranging from 47% to 51% compared to 31% in 2024.

  • NeuroOne報告了第四季度的產品營業收入爲130萬美元,相較於去年有所減少,這歸因於取消訂單以過渡到新OneRF產品線。

  • 2024財年的產品營業收入激增77%,達到350萬美元。

  • 預計2025財年的營業收入在800萬美元至1000萬美元之間,代表132%至190%的增長。

  • 預計在2025財年,毛利率將改善,範圍爲47%至51%,而2024年爲31%。

Business Progress:

業務進展:

  • Successfully achieved FDA 510(k) clearance for the OneRF Ablation System and secured a strategic partnership for distribution.

  • Expanded partnership with Zimmer Biomet, improving distribution potential in the U.S. and certain overseas geographies.

  • Initiated commercialization of OneRF Ablation System with strong early adoption and interest, evidenced through completed procedures and physician training.

  • Pursuing additional medical applications for RF Ablation and advancing novel technologies for spinal cord stimulation and drug delivery.

  • 成功獲得了OneRF消融系統的FDA 510(k)認證,並獲得了分銷的戰略合作伙伴關係。

  • 與Zimmer Biomet擴展合作,提升在美國及某些境外地區的分銷潛力。

  • 啓動OneRF消融系統的商業化,且通過完成的手術和醫生培訓顯示出強烈的早期採用和興趣。

  • 追求RF消融的額外醫療應用,推進脊髓刺激和藥物輸送的新型技術。

Opportunities:

機會:

  • The expanded partnership with Zimmer Biomet enhances sales proliferation and profitability.

  • Pursuit of new medical applications (e.g., for trigeminal neuralgia and potentially lower back and knee pain) provides competitive differentiation and potential revenue streams not currently in the 2025 guidance.

  • 與Zimmer Biomet的擴展合作增強了銷售增長和盈利能力。

  • 追求新的醫療應用(例如,三叉神經痛以及可能的下背部和膝蓋疼痛)提供了競爭差異化和潛在的營業收入來源,這些在2025指導中尚未體現。

Risks:

風險:

  • Initial slow uptake and scaling required for new medical technologies such as the OneRF Ablation System present risks to expected revenue growth.

  • The development and approval of new applications like for trigeminal neuralgia present uncertainties and potential delays.

  • OneRF消融系統等新醫療技術的初期緩慢接受和規模化要求對預期的營業收入增長構成風險。

  • 對三叉神經痛的新應用程序的開發和批准存在不確定性和潛在的延遲。

More details: NeuroOne Medical IR

更多詳情:NeuroOne醫療投資者關係

Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.

提示:欲了解更全面的細節,請參閱IR網站。 文章僅供投資者參考,不構成任何指導或推薦建議。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
評論 評論 · 瀏覽 231

熱點推薦

搶先評論

聲明

本頁的譯文內容由軟件翻譯。富途將竭力但卻不能保證翻譯內容之準確和可靠,亦不會承擔因任何不準確或遺漏而引起的任何損失或損害。